Brief: Genmab, Seagen Announce That Tivdak Met Its Primary Endpoint Of Improved Overall Survival In Patients With Recurrent Or Metastatic Cervical Cancer Compared To Chemotherapy

Seagen

04/09/2023 20:02

Sept 4 (Reuters) - Genmab A/S  GMAB.CO :
    * GENMAB AND SEAGEN ANNOUNCE THAT TIVDAK® (TISOTUMAB
VEDOTIN-TFTV)
MET ITS PRIMARY ENDPOINT OF IMPROVED OVERALL SURVIVAL IN
PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER COMPARED
TO CHEMOTHERAPY
    * GENMAB A/S - GENMAB AND SEAGEN TO ENGAGE IN DISCUSSIONS
WITH
REGULATORY AUTHORITIES
    * GENMAB A/S - PHASE 3 INNOVATV 301 CONFIRMATORY TRIAL MET
ITS
PRIMARY ENDPOINT OF IMPROVED OS AT PREDETERMINED, INDEPENDENT
INTERIM ANALYSIS
    * GENMAB A/S - INNOVATV 301 CHINA EXTENSION STUDY HAS BEEN
INITIATED AND CONTINUES TO ENROLL PATIENTS, IN COLLABORATION
WITH ZAI LAB LIMITED
    * GENMAB A/S:KEY SECONDARY ENDPOINTS OF
INVESTIGATOR-ASSESSED
PROGRESSION-FREE SURVIVAL,OBJECTIVE RESPONSE RATE DEMONSTRATED
STATISTICAL SIGNIFICANCE

Source text for Eikon:  ID:nGNX8V3smD 
Further company coverage:  GMAB.CO 

 ((Reuters.Briefs@thomsonreuters.com;))